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The HIV pandemic has contributed greatly to the emergence of
opportunistic fungal pathogens and increased incidence of
opportunistic fungal infections over the last two decades;1 the
morbidity and mortality impact is especially pronounced in
sub-Saharan Africa. A systematic review of African cohort
studies and selected cross-sectional studies in HIV-infected
patients reported incidence rate ranges for three common
fungal opportunistic infections: oral candidiasis (3.8 - 43.8
cases/100 person-years-observation (PYO)), cryptococcosis
(0.3 - 4 cases/100 PYO) and Pneumocystis jirovecii pneumonia
(PCP) (0 - 0.5 cases/100 PYO).2 Cryptococcosis caused 44% of
deaths in a cohort of HIV-infected South African miners and
was the third commonest infectious cause for hospitalisation.3
South African adult and paediatric studies have shown that
PCP accounts for 20 - 52% of community-acquired
pneumonia in hospitalised HIV-infected patients.4 This review
aims to provide a guide for clinicians to using the clinical
microbiology laboratory for the management of common HIV-
associated opportunistic fungal infections. Close interaction
with the local laboratory is recommended to facilitate
awareness of the spectrum of laboratory tests on offer (Table
I), to guide appropriate specimen collection and to assist with
interpretation of laboratory test results.
MUCOSAL CANDIDIASIS
Candidiasis almost always presents as mucocutaneous disease 
in HIV-infected patients; the disseminated form of disease
only occurs in the presence of additional predisposing factors.5
Oropharyngeal candidiasis (OPC) is one of the commonest
HIV-associated opportunistic fungal infections, occurring at
CD4+ T-cell counts as high as 300 cells/µl. OPC is usually
diagnosed clinically by visualisation of the typical white
pseudomembranous (Fig. I) or hypertrophic forms. Laboratory
diagnosis, by examination of mucosal scrapings, is useful for
less typical forms, e.g. erythematous OPC. Oesophageal
candidiasis (OC) occurs at lower CD4+ T-cell counts (<100
cells/µl). The diagnosis is usually made clinically (dysphagia or
odynophagia in the presence/absence of OPC). Endoscopic
examination and mucosal biopsy (or brushings/scrapings) to
confirm the diagnosis is reserved for failure of empiric therapy
or for severe disease requiring hospitalisation.6 Vulvovaginal
candidiasis (VVC) in HIV-infected women occurs at all CD4+ T-
cell counts with manifestations that are similar to those in
immunocompetent women. Laboratory diagnosis may be
considered in cases where complicated vulvovaginitis
(infection with Candida species other than C. albicans) is
possible, e.g. prior chronic use of fluconazole in HIV-infected
women.7 Antifungal susceptibility testing (AST), although well
standardised for a number of organism-drug combinations
with validated interpretive breakpoints,8 is not routinely
indicated for mucosal candidiasis. AST may be requested in
treatment-refractory cases,9 if the laboratory has the capacity
to perform testing using a standardised method. 
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This review aims to provide a guide for clinicians to using the clinical microbiology laboratory for management of common
HIV-associated opportunistic fungal infections, e.g. mucosal candidiasis, cryptococcosis, Pneumocystis jirovecii pneumonia
(PCP), histoplasmosis, etc. Laboratory tests provide valuable guidance at various stages of management of HIV-infected
patients with fungal infections: (i ) establishing a diagnosis, (ii ) guiding appropriate antifungal therapy in selected
circumstances, (iii ) providing laboratory prognostic markers, (iv ) monitoring response to therapy; and (v ) detecting relapses.
However, the laboratory is not always able to provide reliable answers to clinically relevant questions, and these limitations
must be considered in the interpretation of test results.
Fig. 1. Pseudomembranous oropharyngeal candidiasis in an
HIV-infected adult patient (courtesy Dr Kerrigan McCarthy).
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When is it 
appropriate  
to use the
Common site/s laboratory Clinical Appropriate
Fungus of infection for diagnosis? specimen laboratory test Comments
Candida species Oropharyneal, Atypical forms Mucosal Microscopy Provides a rapid 
oesophageal and scrapings, presumptive diagnosis
vulvovaginal brushings or
mucosa biopsy Culture Provides confirmation of 
diagnosis and species  
identification which may guide 
choice of antifungal therapy
within days
Cryptococcus Meninges and brain All suspected cases Cerebrospinal Microscopy Provides a rapid
species fluid (India ink) presumptive diagnosis.
Sensitivity and specificity is 
good in a high prevalence 
setting (compared with 
culture)
Culture Provides confirmation of 
diagnosis but may be slow 
(up to 2 weeks in some cases)
Antigen test Rapid and is highly sensitive
and specific (compared with 
culture)
Not universally available in 
South African laboratories
Blood (or serum) Culture Provides confirmation of 
diagnosis but is slow (up to 
2 weeks)
Antigen test Rapid and highly sensitive and 
specific (compared with 
culture)
Not universally available in 
South African laboratories
Pneumocystis Pulmonary All suspected cases Induced sputum, Direct Sensitivity improves as
jirovecii bronchoalveolar immunofluorescence the test is performed
lavage, lung microscopy on more invasively 
biopsy, etc. obtained respiratory tract 
specimens
Not universally available in 
South African laboratories
Histoplasma Disseminated (skin, All suspected cases Skin biopsy, blood, Microscopy Provides a rapid presumptive
capsulatum blood, bone marrow, bone marrow diagnosis
etc.) biopsy, etc.
Culture Provides confirmation of
diagnosis but is very slow
(up to 6 weeks)
Urine or serum Antigen test Rapid and has excellent 
sensitivity and specificity – 
especially with urine 
specimens
Not available in South African 
laboratories at present
Dermatophyte Superficial Atypical forms Skin scrapings, Microscopy Provides a rapid presumptive 
infections (cutaneous) nail and hair diagnosis
clippings
Culture Provides diagnostic confirmation
but is slow (weeks)
TABLE I.  DIAGNOSIS OF COMMON HIV-ASSOCIATED OPPORTUNISTIC FUNGAL INFECTIONS
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CRYPTOCOCCOSIS
Acquired immune deficiency syndrome (AIDS)-associated
cryptococcosis usually presents at low CD4+ T-cell counts
(<100 cells/µl); the median CD4+ T-cell count at time of initial
diagnosis in a Ugandan cohort study was 17 cells/µl.10
Although the clinical manifestations of symptomatic incident
disease are varied, meningoencephalitis is the commonest
presentation. Ninety-seven per cent of laboratory-confirmed
incident cases, detected by population-based surveillance for
cryptococcosis in Gauteng, presented with symptoms or signs
of meningoencephalitis.11 However, an autopsy study of South
African miners has shown that cryptococcal pneumonia may
be more common than previously thought and under-
diagnosed in life.12 Cerebrospinal fluid (CSF), submitted to a
laboratory for diagnosis of a symptomatic incident episode,
may be subjected to a number of tests which provide differing
levels of diagnostic sensitivity and specificity compared with
the reference standard method (culture), which provides a
definitive diagnosis. These tests are widely utilised because
culture of Cryptococcus species is not universally available in
South African laboratories as a diagnostic tool. Most
cryptococcal isolates will be detected on standard fungal and
bacterial media within 48 - 72 hours, but longer periods (up to
2 weeks) may be required to produce visible colonies,
particularly if the fungal burden is low (early disease or prior
antifungal therapy).13 The sensitivity of the inexpensive India
ink staining technique (Fig. 2) compared with culture has been
estimated to be 98% in an antiretroviral therapy (ART)-naïve
South African population (compared with a somewhat lower
sensitivity (79 - 88%) in developed countries in the pre-ART
era14,15); this may be related to the late presentation of patients
with a high CSF fungal burden and/or experienced laboratory
personnel.11 The cryptococcal antigen (CrAg) test is available in
two formats: latex agglutination assay and enzyme-linked
immunosorbent assay (ELISA). The more widely available latex
agglutination test (Fig. 3), usually performed on either CSF or
serum, has excellent sensitivity (93 - 100%) and specificity
(93 - 98%) compared with culture for diagnosis of incident
cryptococcosis.16 Rare false-negative17-21 and false-positive22-33
CrAg test results have been reported. CrAg specificity may be
improved when titres ≥8 are reported as positive by the
laboratory.34 It may be most cost-effective to reserve use of the
CrAg test for diagnosis of incident episodes where the India
ink test is negative despite a compatible clinical and laboratory
picture (CSF CrAg) or if a lumbar puncture is contraindicated
(serum CrAg).35 The CrAg test can provide semi-quantitative
results; titres of >1 024 at baseline (which correlate with
baseline CSF cryptococcal colony-forming units) have been
associated with increased risk of death at 10 weeks.36,37 Many
South African laboratories provide only qualitative results for
the CrAg test. Culture of blood, using standard automated
blood culturing systems, e.g. BacT/Alert (Biomerieux Inc.,
Durham, NC), may provide additional evidence for the initial
diagnosis of cryptococcosis. However, the sensitivity (73%) is
somewhat lower than CSF culture.11 Screening HIV-infected
patients at risk for cryptococcal infection with the serum CrAg
test remains an unresolved issue, especially related to
management of patients with isolated positive
antigenaemia.38 Whereas there is some evidence for screening
in high-prevalence settings,34,39,40 no benefit has been shown
in low-prevalence settings.41,42 Monitoring CrAg titres
following diagnosis of incident disease is not recommended.43-45
Diagnostic challenges become more pronounced in patients
receiving ART.46 The interpretation of the serum CrAg test
result in patients who become CrAg test negative after
antifungal treatment, discontinue secondary antifungal
prophylaxis and revert to CrAg test positivity is unclear.47
Similarly, the utility of the CrAg test in detecting immune
reconstitution inflammatory syndrome (IRIS)-associated
culture-negative episodes of cryptococcosis remains
uncertain.48 AST of Cryptococcus species is complex; however,
a reference method has been developed.8 Commercial tests,
e.g. E-test (AB Biodisk, Solna, Sweden), produce minimum
inhibitory concentration (MIC) results with reasonable
concordance to the reference method.49 However, when the
E-test is used to predict fluconazole MICs, 1 - 2-fold higher
MICs are produced compared with the reference CLSI method
(Beth Arthington-Skaggs – personal communication). It is
important to note that interpretive breakpoints, which allow
Fig. 2. India ink preparation of cerebrospinal fluid from a
patient with cryptococcal meningitis showing a budding yeast
cell of Cryptococcus neoformans surrounded by the
characteristic large capsule (courtesy Professor David Ellis,
Kaminski’s Digital Image Library,
http://www.mycology.adelaide.edu.au).
Fig. 3. Cryptococcal latex antigen test showing a positive
agglutination reaction (courtesy Professor David Ellis,
Kaminski’s Digital Image Library,
http://www.mycology.adelaide.edu.au).
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the MIC to be categorised as ‘susceptible’ or ‘resistant’, are not
clearly defined owing to limited clinical outcome data.50,51
Given that 99% of MIC results of amphotericin B in a global
survey clustered below 1 µg/ml,52 it should be evident that
testing amphotericin B is of little value in routine practice.
There may be a limited role for investigation of fluconazole
‘resistance’ in recurrent cryptococcal episodes where the
laboratory has the capacity to perform a well-standardised
quality-controlled test on both incident and recurrent isolates
in parallel.35 Interpretation of these AST results requires expert
input.
PNEUMOCYSTIS JIROVECII PNEUMONIA
PCP, caused by the recently reclassified human fungal
pathogen P. jirovecii, rarely occurs in patients with CD4+ T-cell
counts >250 cells/µl.53 The diagnosis of PCP in patients with
AIDS is facilitated by the relatively higher organism burden in
the lungs compared with non-AIDS patients; however,
diagnosis may be impeded by lack of clinical suspicion,
concurrent use of prophylactic drugs and polymicrobial lung
infection in patients with AIDS.54 P. jirovecii cannot be cultured
in vitro. Laboratory diagnosis hinges on microscopic
examination of the fungus using techniques which reveal the
cyst, trophic or both forms. The cyst form may be visualised
using the Gomori methenamine silver, toluidine blue O, cresyl
echt violet or calcofluor white stains; trophic forms are
visualised by modified Papanicolaou, Gram-Weigert or
Wright-Giemsa stains. Monoclonal antibody techniques (e.g.
immunofluorescence assay (IFA)), which can detect both
forms, are now widely used because of improved sensitivity
and specificity compared with conventional stains in induced
sputum samples.54 Optimal respiratory tract specimen
collection facilitates diagnosis: the sensitivity and specificity
of the IFA was determined to be 90.6% and 100% respectively
for sputum specimens and 96.3% and 100% respectively for
bronchoalveolar lavage specimens in one study.55 Induced
sputum, which is less invasively obtained than a
bronchoscopically obtained specimen yet is superior to
expectorated sputum, is recommended as a first-line specimen
to diagnose PCP in patients with AIDS.54,56 Clinicians often
treat for PCP empirically in symptomatic patients at risk of
infection; however, widespread laboratory test availability and
improved laboratory turnaround time should facilitate use of
laboratory diagnostic tests. Use of the polymerase chain
reaction (PCR) to amplify fungal DNA directly from clinical
specimens remains an investigational tool, which is not
currently widely available. PCR is more sensitive than
conventional methods and may be able to detect colonisation
by the organism in asymptomatic HIV-infected patients.57 PCR
may also be used to investigate genetic mutations which
potentially confer resistance to trimethoprim-sulfametho-
xazole.58
HISTOPLASMOSIS
Histoplasmosis, an AIDS-defining illness since 1987,59 is 
caused by the dimorphic fungus Histoplasma capsulatum.
Only the ‘classic’ var. capsulatum form has been described in
South Africa.60 The progressive disseminated form of
histoplasmosis (PDH), the commonest manifestation in AIDS
patients, occurs at CD4+ T-cell counts <50 cells/µl53 and may
mimic disseminated tuberculosis.61 Culture provides a
definitive diagnosis (Fig. 4); however, H. capsulatum is a slow-
growing pathogen requiring up to 6 weeks.62 Various
specimens may be submitted for culture: (i ) specimens which
can be obtained relatively non-invasively, e.g. biopsies of
skin/mucosal lesions, blood or urine, should be submitted in all
cases; and (ii ) deeper tissues, e.g. bone marrow, may be
submitted, if indicated, to improve the diagnostic yield. It is
important to note that appropriate blood culturing systems
are required to detect H. capsulatum, e.g. Isolator lysis-
centrifugation system (Wampole Laboratories, Cranbury, NJ).
Automated blood culturing systems like BACTEC (Becton
Dickinson, Sparks, Md) and BacT/Alert (Biomerieux Inc.,
Durham, NC) do not yield growth reliably.63 The high organism
load in AIDS patients facilitates a high sensitivity (urine 95%,
serum 86%) and specificity (99%) of the H. capsulatum
antigen test (MiraVista laboratories, Indianapolis, USA) for
diagnosis of incident disease. This antigen test is extremely
useful to monitor response to therapy and detect relapses;
titres correspond closely to the clinical course of disease.64 The
H. capsulatum antigen test is available to South African
clinicians through MiraVista laboratories (Indianapolis, USA)
(Joe Wheat – personal communication); however, the high
cost of the test, international shipping of the specimen and
delayed turnaround time may be prohibitive from a clinical
diagnostic standpoint. Serological diagnostic tests have
limited sensitivity (up to a quarter are negative) in
immunocompromised patients and are not widely available.
Many clinicians rely on histopathological methods to provide
a tentative diagnosis; however, it is important to realise that
sensitivity is low (<50%), false positives may be reported
because it may be difficult to distinguish other yeasts or
staining artifacts from H. capsulatum, and persistence of non-
Fig. 4. Microscopic view of the mycelial form of Histoplasma
capsulatum showing the characteristic tuberculate
macroconidia formed on short condiophores (courtesy
Professor David Ellis, Kaminski’s Digital Image Library,
http://www.mycology.adelaide.edu.au). 
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viable H. capsulatum yeasts in tissue for prolonged periods
after acute infection may complicate the diagnosis.64
OTHER FUNGAL OPPORTUNISTIC INFECTIONS
Dermatophyte infections have not increased in incidence in 
HIV-infected patients,65 but may present with: (i ) a more
widespread body distribution, e.g. tinea capitis in adults (Fig.
5); (ii ) more disfiguring lesions, e.g. hyperkeratotic lesions; (iii)
atypical lesions, e.g. ‘anergic’ tinea corporis lacking typical
central clearing and defined elevated borders; and (iv ) poor
clinical response to therapy.66 The laboratory can assist with
the definitive diagnosis of atypical or non-responsive
dermatophytosis, if keratinised tissue samples are provided,
e.g. skin scrapings, nail or hair clippings. Invasive aspergillosis
(IA) is rare in patients with AIDS, usually requiring the
presence of additional immunocompromising factors, e.g.
neutropenia or high-dose corticosteroids, to occur.5 Diagnosis
of IA is definitively established by demonstration of hyphae in
tissue in the presence of clinically compatible disease.
Colonisation of the airways may be a ‘red herring’ and limits
the usefulness of respiratory tract specimen culture for
diagnostic purposes. Disseminated sporotrichosis, presenting
as cutaneous, osteoarticular, pulmonary or meningeal disease,
has been infrequently diagnosed and reported in South
African AIDS patients.65 A presumptive diagnosis of
sporotrichosis may be established by visualisation of the
typical ‘cigar-shaped’ yeasts in tissue specimens; culture of
the slow-growing fungus from tissue or body fluids will
confirm the diagnosis. Endemic and tropical mycoses, e.g.
blastomycosis and eumyectoma, have not increased over time
parallel to HIV incidence rates in South Africa.65 Mycoses that
are AIDS-defining in other regions of the world, e.g.
Penicillium marneffei in South East Asia, have not been
reported in South African AIDS patients.65
CONCLUSIONS
Laboratory tests can provide valuable guidance at various 
stages of management of HIV-infected patients with fungal
infections: establishing a diagnosis, guiding appropriate
antifungal therapy in selected circumstances, providing
laboratory prognostic markers, monitoring response to
therapy and detecting relapses. However, there are important
limitations that require consideration. Current laboratory
methods are not always able to provide a definitive diagnosis
owing to limited sensitivity and specificity. Tests that provide
a qualitative result are not always able to distinguish fungal
colonisation from disease. Antifungal susceptibility testing,
although standardised for some pathogenic fungi, provides
complex challenges for the laboratory with regard to
performance and interpretation; the laboratory is not easily
able to provide a ‘susceptible’ or ‘resistant’ answer to guide
management.67
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